A new reality for Immunocore
A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.
Autolus slams on the brakes in its Car
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
Bracco’s Blue Earth buy boosts Syncona
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Ash 2018 preview – blood cancers offer biotech a chance at redemption
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
Flush with cash, Allogene tackles the production conundrum
In the seven months since its founding the company has attracted $793m of financing. Now it must execute.
Allogene spells out its interest in Cellectis
As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…
The first real challenge to multiple myeloma CAR-T therapy
Amgen’s AMG 420 yielded early but spectacular remissions, leaving Boehringer Ingelheim with egg on its face.
June rush drives near-record quarter for biotech flotations
Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.